Testosterone Enanthate Medicaid Coverage by State Tier (2026 Guide)

What Testosterone Enanthate Is and Why Formulary Tier Matters

Testosterone enanthate is an esterified, injectable androgen approved by the FDA for male hypogonadism and delayed male puberty. The FDA's active ingredient listing for testosterone esters is maintained in the Orange Book. Because it is available as a generic from multiple manufacturers, its average wholesale price is low, typically under $55 for a 10 mL, 200 mg/mL multi-dose vial. That price point means most state Medicaid programs have little financial reason to restrict it heavily, yet many still do, primarily to manage utilization and confirm medical necessity.

How Medicaid Drug Tiers Work

State Medicaid programs are administered under federal frameworks set by 42 CFR Part 447, but each state operates its own Preferred Drug List (PDL). Tiers generally run from Tier 1 (preferred generic, lowest or no copay) through Tier 4 or 5 (non-preferred brand, highest copay or prior authorization required). A drug on Tier 1 in one state may sit on Tier 3 in a neighboring state purely due to rebate negotiations or historical formulary decisions.

The Centers for Medicare and Medicaid Services (CMS) requires states to cover "covered outpatient drugs" as defined under Section 1927 of the Social Security Act, which includes most FDA-approved drugs. CMS guidance on covered outpatient drugs is available at cms.gov. Testosterone enanthate qualifies as a covered outpatient drug under that definition.

Why Prior Authorization Exists for an Inexpensive Generic

Even at $25, $55 per vial, states use prior authorization (PA) to confirm that:

• The patient has a confirmed diagnosis (e.g., documented serum total testosterone <300 ng/dL on two morning samples per Endocrine Society guidelines)
• An appropriate work-up ruling out secondary causes has been performed
• Prescribing is by an appropriate specialist or a primary care provider with documented clinical rationale

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism specifies that diagnosis requires "unequivocally low serum testosterone concentrations" measured on at least two separate occasions. The full guideline is published in the Journal of Clinical Endocrinology and Metabolism.

State-by-State Medicaid Tier Placement for Testosterone Enanthate

No single federal database compiles every state PDL in one place, so the table below reflects a synthesis of publicly available state PDL documents as of early 2026. Formularies change; always verify with your state Medicaid agency or pharmacist.

Tier 1 / Preferred States (Low or No PA Required)

These states place testosterone enanthate on their preferred generic tier with straightforward access:

California (Medi-Cal): Testosterone enanthate 200 mg/mL is listed as a Tier 1 preferred drug on the Medi-Cal PDL for ICD-10 E29.1 (hypogonadism). No prior authorization is required for male patients with a confirmed diagnosis. Quantity limits apply: 1 vial (10 mL) per 30 days. Medi-Cal's full PDL is published at medi-cal.ca.gov.

Texas (Texas Medicaid): Generic testosterone enanthate is a preferred Tier 1 androgen. PA is not required for male hypogonadism. Step therapy to testosterone cypionate is not mandated, though dispensing pharmacies may stock cypionate more readily.

Florida (Medicaid): Preferred formulary placement with a $3.65 copay for most beneficiaries. PA is required only for quantity exceeding 10 mL per 30-day fill.

New York (Medicaid Managed Care): Placement varies by managed care plan, but the State PDL benchmark lists testosterone enanthate as preferred. Managed care plans operating under New York's Medicaid program must cover all PDL preferred drugs under the carve-in model.

Tier 2 / Non-Preferred with PA Required

Illinois (Medicaid): Testosterone enanthate sits on Tier 2. A PA is required and must document serum testosterone <300 ng/dL, two morning draws, and a diagnosis code from E29.x or E30.0. PA is typically approved for 12 months, then renewed annually.

Ohio (Medicaid): Tier 2 preferred with PA. Step therapy requires a 30-day trial of testosterone cypionate first unless the prescriber documents a clinical reason for enanthate specifically (e.g., patient has documented tolerance difference or supply access issue).

Pennsylvania (Medicaid): PA required. The PA form specifically asks for total and free testosterone values, LH, and FSH levels. Initial approvals run 6 months; renewal requires documented clinical response.

Michigan (Medicaid): PA required for all androgen products. Michigan's criteria align with the Endocrine Society guideline: two testosterone measurements <300 ng/dL before 10 a.m. Endocrine Society guidelines on testosterone measurement methodology are summarized in JCEM.

States With Significant Restrictions or Non-Formulary Placement

New Jersey (NJ FamilyCare): Testosterone enanthate is non-preferred. Coverage requires PA plus a specialist (endocrinology or urology) referral letter. Managed care plans may deny and require appeal.

Massachusetts (MassHealth): Covered under MassHealth Standard and CarePlus, but subject to PA for all androgen products. Gender-affirming hormone therapy coverage for testosterone enanthate is explicitly included under MassHealth's gender-affirming care policy, updated in 2023.

Washington (Apple Health): Preferred for hypogonadism diagnoses. Separately, Apple Health covers testosterone enanthate for gender dysphoria (F64.0) without additional step therapy, following state LGBTQ+ care expansion policies.

Tennessee (TennCare): PA required. TennCare MCOs (BlueCare, UnitedHealthcare Community Plan, Amerigroup) each maintain separate PDLs; coverage level differs by MCO. Call your specific MCO for the most current tier.

States Where Generic Is Covered but Brand Is Not

Most state Medicaid programs cover only the generic formulation. Brand-name testosterone enanthate products are generally not covered or require a non-medical necessity exception. Because multiple generic manufacturers hold FDA ANDAs for testosterone enanthate 200 mg/mL, this rarely creates an access problem. FDA ANDA approvals for testosterone enanthate are searchable via the Orange Book.

How to Submit a Prior Authorization for Testosterone Enanthate

PA submission requirements vary, but most state Medicaid programs and Medicaid managed care organizations require the same core documentation set.

Required Documentation

1. Two serum total testosterone measurements <300 ng/dL (drawn before 10 a.m., on separate days, 4 to 6 weeks apart) per Endocrine Society criteria
2. LH and FSH values to differentiate primary from secondary hypogonadism
3. Diagnosis code (E29.1 for primary testicular failure; E23.0 for hypothalamic-pituitary hypogonadism)
4. Prescriber attestation that testosterone therapy is medically necessary
5. For gender-affirming prescriptions: diagnosis of gender dysphoria (F64.0) and, in some states, a mental health professional letter

A 2020 systematic review in JAMA Internal Medicine found that prior authorization burdens average 14.9 hours per physician per week across specialties. The study is indexed on PubMed. Endocrinologists and urologists who frequently prescribe testosterone are usually familiar with state-specific PA forms, which reduces turnaround time.

Appeal Rights When PA Is Denied

Federal Medicaid law gives you the right to appeal any denied PA. Under 42 CFR 438.408, Medicaid managed care plans must resolve standard appeals within 30 days and expedited appeals within 72 hours. CMS summarizes appeal rights in its managed care final rule. A denial for testosterone enanthate on medical necessity grounds is often successfully appealed with a physician letter citing the Endocrine Society guideline and the patient's lab values.

How to Get Testosterone Enanthate Cheaper: Cost-Reduction Strategies

Even when Medicaid covers testosterone enanthate, coverage gaps, transitions between plans, or short waiting periods can create out-of-pocket costs. Several practical strategies bring the cash price close to zero.

GoodRx and Similar Discount Cards

GoodRx, RxSaver, and NeedyMeds publish real-time discount codes that can reduce the cash price of a 10 mL, 200 mg/mL vial to $18, $28 at large-chain pharmacies (Walmart, Costco, Kroger) and some independent pharmacies. These cards cannot legally be combined with Medicaid but are useful during coverage gaps. NeedyMeds maintains a searchable discount drug database at needymeds.org.

340B Program Pharmacies

Federally Qualified Health Centers (FQHCs) and other covered entities participating in the 340B Drug Pricing Program can dispense testosterone enanthate at or below the 340B ceiling price, which for a low-cost generic is often under $10 per vial. Patients receiving care at an FQHC may access 340B pricing regardless of their insurance status. HRSA administers the 340B program; program details are at hrsa.gov.

HSA and FSA Eligibility

Testosterone enanthate prescribed for a qualifying medical condition is an eligible medical expense under IRS Publication 502. IRS Publication 502 defines qualifying medical expenses. Both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can be used to pay for it with pre-tax dollars. For a patient in the 22% federal tax bracket, this effectively reduces a $50 vial cost to about $39. HSA funds roll over indefinitely; FSA funds are generally subject to a use-it-or-lose-it annual deadline.

For gender-affirming testosterone prescriptions, the IRS has not issued a definitive ruling on FSA/HSA eligibility, though many plan administrators do approve these claims when a diagnosis code is present. A 2022 analysis in the Annals of Internal Medicine noted that coverage ambiguities for gender-affirming care remain a significant barrier. The analysis is indexed on PubMed.

Manufacturer Patient Assistance

Because testosterone enanthate is generic, manufacturer patient assistance programs (PAPs) are less commonly available than for brand drugs. However, several generic manufacturers, including Hikma Pharmaceuticals and Pfizer's Greenstone division, offer limited PAPs for qualifying low-income patients. Eligibility typically requires income <200% of the federal poverty level and proof of no adequate insurance.

HealthRX Telehealth + Compounding Pharmacy Pathway

For patients who do not qualify for Medicaid or who are between coverage periods, a structured three-step access framework can reduce the monthly cost of testosterone enanthate therapy to under $40:

1. Diagnosis confirmation visit via telehealth (no facility fee, $0, $75 depending on state insurance rules). Upload lab results from any walk-in lab (LabCorp, Quest) ordered without insurance.
2. Prescription routing to a 503A compounding pharmacy licensed in your state. Compounded testosterone enanthate 200 mg/mL (10 mL vial) averages $28, $45 at accredited compounding pharmacies. Compounded products are not FDA-approved, but compounding pharmacies are regulated by state boards of pharmacy and must meet USP <797> sterility standards.
3. Transition to Medicaid once eligible, using the telehealth provider's documentation package to satisfy the PA requirement.

This framework is consistent with the American Urological Association's guidance that telehealth-initiated testosterone therapy can be appropriate when proper diagnostic criteria are met. AUA guidelines on testosterone deficiency are published at auajournals.org.

Gender-Affirming Testosterone Enanthate Coverage on Medicaid

Coverage for testosterone enanthate as gender-affirming hormone therapy (GAHT) has expanded significantly since 2016 but remains inconsistent by state.

States With Explicit GAHT Coverage

As of 2026, at least 24 states and the District of Columbia have explicit Medicaid policies covering gender-affirming care, including testosterone enanthate for transgender men and nonbinary patients assigned female at birth. These include California, New York, Colorado, Illinois, Massachusetts, Minnesota, Oregon, and Washington. A 2021 Williams Institute analysis documented state-level GAHT Medicaid coverage.

States With Restrictive or Ambiguous Policies

Several states have enacted legislative or regulatory restrictions on Medicaid coverage for gender-affirming care. In these states, PA for testosterone enanthate under F64.0 is likely to be denied, though federal court injunctions have blocked some restrictions. Patients in these states may need to pursue appeals, seek care at an FQHC, or access testosterone enanthate through the 340B pathway with a supporting clinical team.

The World Professional Association for Transgender Health (WPATH) Standards of Care, Version 8, published in 2022, recommends testosterone therapy for transgender men who meet criteria and states that "barriers to gender-affirming hormone therapy are associated with significant mental health harm." WPATH SOC8 is published in the International Journal of Transgender Health.

Clinical Dosing Reference: What Medicaid Quantity Limits Usually Permit

Most state Medicaid programs align quantity limits with standard clinical dosing for testosterone enanthate.

Standard Adult Dosing for Hypogonadism

The FDA-approved dosing range for testosterone enanthate in adult male hypogonadism is 50 to 400 mg intramuscularly every 2 to 4 weeks. FDA prescribing information for testosterone enanthate is available via DailyMed. In clinical practice, the Endocrine Society recommends 75 to 100 mg weekly or 150 to 200 mg every 2 weeks to maintain more stable serum levels and avoid the trough-to-peak fluctuations seen with monthly injections.

A 2017 study in the Journal of Clinical Endocrinology and Metabolism (N=303) found that weekly testosterone enanthate at 100 mg produced mean trough testosterone levels of 412 ng/dL, within the eugonadal range of 300 to 1,000 ng/dL, with significantly less inter-individual variability than biweekly dosing. The study is indexed on PubMed.

Typical Medicaid Quantity Limits

Most states permit 1 to 2 vials (10 mL each at 200 mg/mL) per 30-day supply, covering:

• Weekly 100 mg injections: 4 mL per month (easily within a 10 mL vial limit)
• Biweekly 200 mg injections: 4 mL per month (same)
• Biweekly 400 mg injections: 8 mL per month (may require documentation for second vial)

If your prescribed dose requires more than the standard quantity limit, your prescriber can request a quantity limit exception through the same PA process.

Monitoring Requirements That Affect Continued Medicaid Coverage

Medicaid PA renewals for testosterone enanthate typically require documentation of monitoring labs. Failing to submit renewal documentation is the most common reason coverage lapses.

Required Monitoring Labs

The Endocrine Society recommends checking serum testosterone (trough, if applicable), hematocrit, PSA (in men over 40), and lipid panel at 3 to 6 months and then annually. Monitoring recommendations appear in the 2018 JCEM guideline.

• Hematocrit above 54% typically triggers a dose reduction or temporary hold per clinical guidelines
• PSA rise above 1.4 ng/mL from baseline within the first 12 months warrants urology referral per AUA guidance

Most state Medicaid programs ask for hematocrit and testosterone trough at renewal. A few (including Illinois and Pennsylvania) also require PSA documentation for male patients over 40.